Monday, November 20, 2017

© Reuters.  Ad Com review Wednesday for Novo Nordisk's semaglutide for T2D© Reuters. Ad Com review Wednesday for Novo Nordisk’s semaglutide for T2D

  • The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet on Wednesday, October 18 to review and discuss Novo Nordisk (CO:NOVOb)’s (NVO +4.4%) New Drug Application (NDA) seeking approval for once-weekly semaglutide as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
  • FDA briefing doc
  • Company briefing doc
  • Now read: Roche Is Almost At The Finish Line

Original article

sponsoredArticle = ‘div-gpt-ad-1466339494851-0’;

Banner Content

FOLLOW US

GOOGLE PLUS

PINTEREST

FLICKR

INSTAGRAM

Archivies